Bio-Connect
Anti Latency-Associated Peptide (LAP) Plasma Kallikrein Degradation Fragment L59 mAb (Clone 6D6)

Anti Latency-Associated Peptide (LAP) Plasma Kallikrein Degradation Fragment L59 mAb (Clone 6D6)

CAC-RIK-MA-L59
Cosmo Bio USA
Product group Antibodies
Sign in to order and to see your custom pricing.
Large volume orders?
Order with a bulk request

Overview

  • Supplier
    Cosmo Bio USA
  • Product Name
    Anti Latency-Associated Peptide (LAP) Plasma Kallikrein Degradation Fragment L59 mAb (Clone 6D6)
  • Delivery Days Customer
    16
  • Certification
    Research Use Only
  • Scientific Description
    Background TGF-beta is produced as a pro-protein in which the 25 kD active TGF-beta is trapped by an N-terminal pro-peptide called Latency Associated Protein (LAP). Upon receipt of certain stimuli a conformational change is induced in a latent complex to release the active TGF-beta from the complex. The resultant TGF-beta binds to cognate signaling receptors and exerts various physiological and pathological activities. This reaction is called TGF-beta activation reaction, which is known to be induced by binding of the latent complex to cell adhesion proteins such as thrombospondin and integrins, and/or by being cleaved by the action of proteases such as serine proteases, cysteine proteases, and MMPs in an organ and context-depending manner. The RIKEN Center for Biomedical Science and Research Center for Liver Cancer Prevention and Research Unit focused on the involvement of the serine protease plasmin and plasma kallikrein in the release and activation of TGF-beta and its involvement in liver diseases. They showed that plasmin and plasma kallikrein cleave, respectively, at 56Lys-57Leu and 58Arg-59Leu within the LAP portion of the latent TGF-beta1 molecule. The anti-TGF-beta1 LAP-degradates (LAP-D) antibodies are useful to investigate the molecular mechanism of TGF-beta activation and its related diseases including liver fibrosis/cirrhosis and liver degeneration. Applications 1. Western Blotting 2. ELISA Source Professor Koichi, National Institute of Advanced Industrial Science and Technology RIKEN Biomedical Science Research Center Liver Cancer Prevention Research Unit Product Description References 1) LAP degradation product reflects plasma kallikrein-dependent TGF-beta activation in patients with hepatic fibrosis, Hara M., Kirita A., Kondo W. et al. Springerplus. May 1; 3: 221. PMCID: PMC4033717 (2014). 2) L59 TGF-beta LAP degradation products serve as a promising blood biomarker for liver fibrogenesis in mice, Hara M., Inoue I., Yamazaki Y. et al. Fibrogenesis Tissue Repair. Sep 15; 8: 17. PMCID: PMC4570586 (2015).
  • UNSPSC
    12352203